Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.37 |
| ▸ | CA2 | P00918 | 9/20 | 0.37 |
| ▸ | CA9 | Q16790 | 6/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA4 | P22748 | 4/20 | 0.37 |
| ▸ | CA6 | P23280 | 4/20 | 0.37 |
| ▸ | CA5A | P35218 | 4/20 | 0.37 |
| ▸ | CA7 | P43166 | 4/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | CA3 | P07451 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PTGES2 | Q9H7Z7 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591942 | 0.82 | ALDH1A1 (0.43) | CA1CA2CA9CA12CA4 | |
| SCHEMBL4033412 | 0.80 | CA1 (0.42) | CA1CA2CA9CA12CA4 | |
| SCHEMBL4185548 | 0.74 | CA2 (0.39) | CA1CA2CA9CA12CA4 | |
| SCHEMBL4183678 | 0.73 | CA2 (0.42) | CA1CA2CA9CA12CA4 | |
| SCHEMBL618887 | 0.72 | HSD11B1 (0.49) | CA1CA2CA9CA12CA4 | |
| SCHEMBL23043571 | 0.71 | ALDH1A1 (0.52) | CA1CA2CA9CA12CA4 | |
| SCHEMBL16758832 | 0.71 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL31527823 | 0.71 | HSD11B1 (0.48) | CA1CA2CA9CA12CA4 | |
| SCHEMBL29688925 | 0.69 | CYP3A4 (0.42) | CA1CA2ALDH1A1LMNATDP1 | |
| SCHEMBL6038911 | 0.69 | CA1 (0.48) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| CN-101301294-A | Combinated inhibitors of FBP-ase and antidiabetic agents for diabetes treatment | METABEHJSIS TERAP JUTIKS INK (US) | 2008-11-12 | — | — | CN | disclosed |
| CN-100396283-C | Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes | METABASIS THERAPEUTICS INC (US) | 2008-06-25 | — | — | CN | disclosed |
| CN-1599612-A | Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes | METABASIS THERAPEUTICS INC (US) | 2005-03-23 | — | — | CN | disclosed |
| EP-1372660-A2 | A COMBINATION OF FBPASE INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | CA1 2648/4885CA2 974/4885CA9 1213/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | CA1 2648/4885CA2 974/4885CA9 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.